
Zymeworks Inc (ZYME) Stock Forecast & Price Target
Zymeworks Inc (ZYME) Analyst Ratings
Bulls say
Zymeworks is a clinical-stage biopharmaceutical company with a diverse portfolio of multifunctional biotherapeutics, including its lead candidate, zanidatamab, which has shown promising results in clinical trials for various cancers. The company's strategic partnerships and potential for multiple revenue streams, through milestones, royalties, and product sales, make it an attractive investment opportunity. However, the inherent risks in the biopharmaceutical industry, such as clinical setbacks or competition from other drugs, must be considered. With the recent FDA approval of zanidatamab and the potential for future successes, the company's positive outlook is driven by its potential for strong financial performance and a robust pipeline.
Bears say
Zymeworks is a clinical-stage biopharmaceutical company that is heavily reliant on the success of its lead candidate, zanidatamab, for revenue. While the recent FDA approval and milestone payment from Jazz Pharmaceuticals are positive developments, the company's product pipeline and financials are heavily dependent on this single asset. Additionally, competition, regulatory and financial risks, as well as uncertainties around potential strategic transactions, could have a significant impact on the company's future performance.
This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.
Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction
Start investing in Zymeworks Inc (ZYME)
Order type
Buy in
Order amount
Est. shares
0 shares